You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSCH-530348
Accession NumberDB05692
TypeSmall Molecule
GroupsInvestigational
DescriptionSCH 530348 is new oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of atherothrombotic events in patients with Acute Coronary Syndrome (ACS), previous Myocardial Infarction (MI), stroke, or existing peripheral arterial disease. On the back of successful phase II clinical trials, SCH 530348 has now progressed to phase III development, where it is being evaluated in two large-scale trials involving almost 30,000 cardiac patients.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • SCH 530348
  • TRA-SCH-530348
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationInvestigated for use/treatment in cardiovascular disorders.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionSCH-530348 is a thrombin receptor antagonist (TRA). It blocks the platelet PAR-1 receptor to which thrombin binds, thus inhibiting thrombin-induced activation of platelets.
TargetKindPharmacological actionActionsOrganismUniProt ID
Proteinase-activated receptor 1ProteinunknownNot AvailableHumanP25116 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabSCH-530348 may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolSCH-530348 may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Acetylsalicylic acid.Approved, Vet Approved
AlprostadilAlprostadil may increase the antiplatelet activities of SCH-530348.Approved, Investigational
AlteplaseSCH-530348 may increase the anticoagulant activities of Alteplase.Approved
ALX-0081SCH-530348 may increase the anticoagulant activities of ALX-0081.Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Aminosalicylic Acid.Approved
AnagrelideSCH-530348 may increase the anticoagulant activities of Anagrelide.Approved
AncrodSCH-530348 may increase the anticoagulant activities of Ancrod.Investigational
AnistreplaseSCH-530348 may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanSCH-530348 may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Apixaban.Approved
ArdeparinSCH-530348 may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSCH-530348 may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinSCH-530348 may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the antiplatelet activities of SCH-530348.Approved
BalsalazideThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Balsalazide.Approved, Investigational
BatroxobinSCH-530348 may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminSCH-530348 may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinSCH-530348 may increase the anticoagulant activities of Bemiparin.Approved
BeraprostSCH-530348 may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinSCH-530348 may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
ButylphthalideSCH-530348 may increase the antiplatelet activities of Butylphthalide.Investigational
CangrelorSCH-530348 may increase the anticoagulant activities of Cangrelor.Approved
CertoparinSCH-530348 may increase the anticoagulant activities of Certoparin.Approved
CilostazolSCH-530348 may increase the anticoagulant activities of Cilostazol.Approved
Citric AcidSCH-530348 may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClopidogrelSCH-530348 may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Collagenase.Approved
Dabigatran etexilateSCH-530348 may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSCH-530348 may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSCH-530348 may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of SCH-530348.Approved, Investigational
DefibrotideSCH-530348 may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when SCH-530348 is combined with dersalazine.Investigational
DesirudinSCH-530348 may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseSCH-530348 may increase the anticoagulant activities of Desmoteplase.Investigational
DextranSCH-530348 may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40SCH-530348 may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70SCH-530348 may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75SCH-530348 may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolSCH-530348 may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Diflunisal.Approved
DipyridamoleSCH-530348 may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleSCH-530348 may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaSCH-530348 may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidSCH-530348 may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSCH-530348 may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinSCH-530348 may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of SCH-530348.Approved, Investigational
eplivanserineSCH-530348 may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of SCH-530348.Approved
EptifibatideSCH-530348 may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateSCH-530348 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FibrinolysinSCH-530348 may increase the anticoagulant activities of Fibrinolysin.Approved
FluindioneSCH-530348 may increase the anticoagulant activities of Fluindione.Investigational
FondaparinuxSCH-530348 may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSCH-530348 may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateSCH-530348 may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of SCH-530348.Approved
HeparinSCH-530348 may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineSCH-530348 may increase the anticoagulant activities of Higenamine.Investigational
HirulogSCH-530348 may increase the anticoagulant activities of Hirulog.Experimental
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with SCH-530348.Approved
IbudilastIbudilast may increase the antiplatelet activities of SCH-530348.Approved, Investigational
Icosapent ethylSCH-530348 may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
idraparinuxSCH-530348 may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilSCH-530348 may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of SCH-530348.Approved, Investigational
IndobufenSCH-530348 may increase the anticoagulant activities of Indobufen.Investigational
Kct 0809SCH-530348 may increase the anticoagulant activities of Kct 0809.Investigational
KetanserinSCH-530348 may increase the antiplatelet activities of Ketanserin.Investigational
LepirudinSCH-530348 may increase the anticoagulant activities of Lepirudin.Approved
LimaprostLimaprost may increase the antiplatelet activities of SCH-530348.Approved
MesalazineThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Mesalazine.Approved
MilrinoneMilrinone may increase the antiplatelet activities of SCH-530348.Approved
NadroparinSCH-530348 may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSCH-530348 may increase the anticoagulant activities of Nafamostat.Investigational
NaftopidilSCH-530348 may increase the antiplatelet activities of Naftopidil.Investigational
NCX 4016The risk or severity of adverse effects can be increased when SCH-530348 is combined with NCX 4016.Investigational
NimesulideNimesulide may increase the antiplatelet activities of SCH-530348.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Obinutuzumab.Approved
OlsalazineThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of SCH-530348.Approved
OtamixabanSCH-530348 may increase the anticoagulant activities of Otamixaban.Investigational
ParnaparinSCH-530348 may increase the anticoagulant activities of Parnaparin.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SCH-530348.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of SCH-530348.Approved, Investigational
PhenindioneSCH-530348 may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonSCH-530348 may increase the anticoagulant activities of Phenprocoumon.Approved
PlasminSCH-530348 may increase the anticoagulant activities of Plasmin.Investigational
PrasugrelSCH-530348 may increase the anticoagulant activities of Prasugrel.Approved
Protein CSCH-530348 may increase the anticoagulant activities of Protein C.Approved
Protein S humanSCH-530348 may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSCH-530348 may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanSCH-530348 may increase the antiplatelet activities of Ramatroban.Investigational
ResveratrolResveratrol may increase the antiplatelet activities of SCH-530348.Experimental, Investigational
ReteplaseSCH-530348 may increase the anticoagulant activities of Reteplase.Approved
ReviparinSCH-530348 may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the antiplatelet activities of SCH-530348.Approved
RivaroxabanSCH-530348 may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneSCH-530348 may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Salicylic acid.Approved, Vet Approved
SelexipagSCH-530348 may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of SCH-530348.Approved, Vet Approved
SRT501SRT501 may increase the antiplatelet activities of SCH-530348.Investigational
StreptokinaseSCH-530348 may increase the anticoagulant activities of Streptokinase.Approved
SulodexideSCH-530348 may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseSCH-530348 may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the antiplatelet activities of SCH-530348.Investigational
TicagrelorSCH-530348 may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineSCH-530348 may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinSCH-530348 may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of SCH-530348.Approved, Investigational
TirofibanSCH-530348 may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Tositumomab.Approved
TranilastSCH-530348 may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrapidilSCH-530348 may increase the antiplatelet activities of Trapidil.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of SCH-530348.Approved, Investigational
TriflusalSCH-530348 may increase the anticoagulant activities of Triflusal.Approved
UrokinaseSCH-530348 may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of SCH-530348.Approved, Nutraceutical, Vet Approved
VorapaxarSCH-530348 may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinSCH-530348 may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSCH-530348 may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150SCH-530348 may increase the anticoagulant activities of Ym150.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thrombin receptor activity
Specific Function:
High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development.
Gene Name:
F2R
Uniprot ID:
P25116
Molecular Weight:
47439.83 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24